Skip to search formSkip to main contentSkip to account menu

TNFRSF17 wt Allele

Known as: Tumor Necrosis Factor Receptor Superfamily, Member 17 wt Allele, TNFRSF13A, B-Cell Maturation Factor Gene 
Human TNFRSF17 wild-type allele is located in the vicinity of 16p13.1 and is approximately 3 kb in length. This allele, which encodes tumor necrosis… 
National Institutes of Health

Related topics

Related topics

15 relations
16p13.1ApoptosisB-Cell Immune Response PathwayB-Cell Maturation Antigen

Broader (1)

TNFRSF17 gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma.
8013 Background: Previous studies indicate patients with relapsed/refractory multiple myeloma (RRMM) who receive high-dose BCMA… 
2019
2019
Novel mutations in the OPN1LW and NR2R3 genes in a patient with blue cone monochromacy
ABSTRACT Background: To clarify the diagnosis of a Chinese patient with novel double heterozygous in the NR2E3 and OPN1LW genes… 
2018
2018
A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal…
Background: B cell maturation antigen (BCMA) has recently emerged as a promising candidate antigen for therapeutic targeting in… 
2017
2017
Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study
Background: Relapsed/refractory MM (RRMM) patients remain highly unmet need. Chimeric antigen receptor (CAR) T cells targeting B… 
Review
2017
Review
2017
Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM
Patients with relapsed/refractory MM (RRMM) rarely obtain durable remissions with available therapies. Clinical use of BCMA… 
2017
2017
Effective Treatment of Relapsed/Refractory Multiple Myeloma Including Extramedullary Involvement By BCMA-Specific Chimeric Antigen Receptor-Modified T Cells
Relapsed and refractory (R/R) multiple myeloma patients have very poor prognosis, especially when they present extramedullary… 
2016
2016
New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)
Novel agents have improved outcomes in MM, but prognosis after patients relapse remains poor and new drugs with novel MoA are… 
2005
2005
Generation and characterization of C305, a murine neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA.
B-lymphocyte stimulator (BLyS) is a member of the tumor necrosis factor (TNF) family and a key regulator of B cell response… 
2001
2001
Presence of four major haplotypes in human BCMA gene: lack of association with systemic lupus erythematosus and rheumatoid arthritis
BCMA (TNFRSF17), along with TACI, has recently been demonstrated to be a receptor for BLyS (TNFSF13B). Recent studies indicated… 
2001
2001
A key role for BAFF in maintaining peripheral B cells.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)